25 Years of Revolutionary Microplate Reader Technology at the LS2
News Dec 16, 2014
BMG LABTECH, the Microplate Reader Company is Gold sponsor of the LS² Annual Meeting 2015 from January 29-30th in Zurich. A visit to booth #33 at the Campus Irchel of the University of Zurich promises a personal introduction to BMG LABTECH’s high performance microplate readers and latest innovations.
Since its establishment in Offenburg, Germany BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies.
25 successful years in the industry attest the quality and reliability of BMG LABTECH’s products and services. BMG LABTECH will showcase the CLARIOstar® with new Atmospheric Control Unit (ACU) and POLARstar® Omega, at the LS2 Annual Meeting 2015 in Zurich, booth #33.
The CLARIOstar® multimode microplate reader offers filter-like performance with advanced LVF Monochromators™ that provides increased sensitivity over conventional monochromators.
The LVF Monochromators™, along with filters and an UV/ Vis spectrometer can be used for a variety of applications in up to eight different detection modes. With its new Atmospheric Control Unit the CLARIOstar® is able to provide the physiological environment for any cell type, enhancing cell-based microplate assays.
The POLARstar® Omega is equipped with an ultra-fast UV/Vis spectrometer and simultaneous dual emission, representing the best combination of performance and flexibility for all life science applications.
The POLARstar® Omega meets the requirements of RT-QuIC seeding assays as it is very robust and the transport system can handle harsh settings, such as long periods of high-speed shaking.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE